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background:  Recent RCTs indicate non-inferiority of percutaneous left atrial appendage (LAA) closure compared to warfarin for stroke 
prevention. The use of percutaneous devices remains controversial due to concerns for complications. We sought to pool the published 
data to compare LAA closure vs warfarin.
Methods:  Medline was searched for RCTs from inception through July, 2014 and meta-analyses were performed using fixed/random 
effects model as appropriate.
results:  Among 2 RCTs, a total of 660 devices were implanted in 732 patients with a 2199 person year (PY) follow-up, implant failure rate 
of 6.9 [95% Confidence interval (CI): 3.7-12.5] per 100 attempted procedures. As compared to warfarin, LAA closure was non-inferior in 
reducing ischemic stroke (IS) and systemic embolism (SE), RR for IS was 1.00 [95% CI: 0.92-1.09] and SE was 1.00 [95% CI: 0.91-1.09] 
respectively (Figure, Panel A). The adjusted incidence rate IS was 1.6 per 100 PY [95% CI: 1.0-2.3], rate of SE was 0.1 per 100 PY [95% 
CI: 0-0.5], rate of cardiovascular or unexplained mortality was 1.2 per 100 PY [95% CI: 0.6-3.0) and rate of hemorrhagic stroke was 0.1 per 
100 PY [95% CI: 0-0.5] in the LAA closure arm. The rate of serious pericardial effusions, major bleed and all complications decreased over 
time (Figure, Panel B).
Conclusion:  Results from our meta-analysis suggest non-inferiority of LAA closure compared to warfarin. There has been reduction in 
implant failure rate and complications associated with LAA closure over time.
 
